DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent disease recurrence. DCprime's product is a whole-cell-based vaccine addressing blood cancers with a high risk of relapse. DCprime is pursuing similar vaccination approaches for solid tumors. DCprime believes relapse vaccines will improve survival by putting the patient's immune system back in control.
| Website | http://www.dcprime.com |
| Revenue | $8 million |
| Employees | View employees |
| Address | 8 Galileïweg, Leiden, South Holland, NL |
| Phone | +31 71 332 2627 |
| Industry | Manufacturing General, Manufacturing |
| Competitors | AstraZeneca, Pfizer, Novartis, Bristol Myers Squibb, Gilead Sciences, Roche, Sanofi, Lilly India, Amgen, Regeneron +37 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies |
Looking for a particular DCPrime BV employee's phone or email?
DCPrime BV Questions
The DCPrime BV annual revenue was $8 million in 2026.
DCPrime BV is based in Leiden, South Holland.
The NAICS codes for DCPrime BV are [3254, 325, 32, 32541].
The SIC codes for DCPrime BV are [283, 28].
Related Companies
